Gout

Poll: Gout and Nonadherence to Therapy

May 2023

Current Issue

May 2023

Volume 63

Issue 5

Research Summaries

FDA Alert

FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose

05/27/2023

Jessica Ganga

The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.

05/27/2023

Research Summary

FLT3 Inhibitor Plus Chemotherapy Improves Survival in Patients with FLT3-mutated Acute Myeloid Leukemia

05/26/2023

Anthony Calabro, MA

Researchers set out to determine the impact of midostaurin in adult patients with FLT3-mutated acute myeloid leukemia.

05/26/2023

Conference Coverage

05/25/2023

Anthony Calabro, MA

Researchers set out to determine whether cancer-related cognitive impairment impacts older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy.

05/25/2023

FDA alert

FDA alert

First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease

05/25/2023

Jessica Ganga

After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.

05/25/2023

Conference Coverage

Conference Coverage

Patient Education in Radiation Oncology

05/22/2023

Anthony Calabro, MA

In her presentation at the 48th ONS Congress, in San Antonio, Texas, Gayle Somerstein, RN, OCN, BSN, MPH, MBA, reviews common adult learning styles that can be tailored to each patient’s individualized...

05/22/2023

Poll

What do you observe as the main reason for nonadherence to urate-lowering therapy among your patients with gout?

Patients tend to feel better between flares.

Patients do not want to begin treatment with another medication.

Patients can be discouraged from continuing treatment if they experience flares at the initiation of urate-lowering therapy.

Submit Answer